- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
David J. Farber
News 11 results
In the News · Source: Managed Healthcare Executive
January 19, 2026
John Shakow and David Farber comment on the limitations of rebates and cost savings for health plans and patients under new Medicare drug programs
In the News · Source: STAT
November 4, 2025
David Farber explains why the expansion of telehealth has driven the increase in compounding in recent years
In the News · Source: Global Legal Chronicle, Law360 Pulse and The AmLaw Litigation Daily
Cases & Deals
Recognition
June 11, 2025
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2025 Guide
In the News · Source: Healthcare Brew
In the News · Source: Law360 Healthcare Authority
Recognition
June 12, 2024
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2024 Guide
In the News · Source: Verywell Health
July 14, 2023
David Farber discusses the FDA recently granting full approval to Leqembi, a drug to treat mild Alzheimer’s disease
Recognition
June 8, 2023
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2023 Guide
Recognition
March 1, 2017
Multiple King & Spalding Attorneys to Serve on 2017 Law360 Editorial Advisory Boards